Additive Effectiveness of Everolimus Plus Tamoxifen Therapy in Treatment of Encapsulating Peritoneal Sclerosis

Simple item page
dc.contributor.authorHuddam, Bulent
dc.contributor.authorAzak, Alper
dc.contributor.authorKocak, Gulay
dc.contributor.authorBasaran, Murat
dc.contributor.authorVoyvoda, Nuray
dc.contributor.authorDuranay, Murat
dc.date.accessioned2023-02-21T12:32:54Z
dc.date.available2023-02-21T12:32:54Z
dc.date.issued2012-01-01
dc.description.abstractPeritoneal dialysis (PD) is one of the commonly used choices of continuous renal replacement therapies. Peritoneal membrane is damaged by using solutions with lower biocompatibility, peritonitis episodes, and vintage of PD therapy. Encapsulating peritoneal sclerosis (EPS) is a rare complication of PD and is presented by progressive fibrosis of the peritoneum. Fibrous tissue entrapment of the intestine, leading to complete intestinal obstruction, is referred to as EPS, the most severe form of sclerosing peritonitis. EPS is irreversible fibrosis of the peritoneal membrane usually associated with high rates of morbidity and mortality. Preventive strategies are the best choice of treatment. Also there is no proven effective therapy for EPS
dc.description.abstractthere are only small-sized trials. Herein we present a case of EPS who improved with everolimus plus tamoxifen therapy.
dc.description.issue3
dc.description.pages387-389
dc.description.volume34
dc.identifier.doi10.3109/0886022X.2011.647338
dc.identifier.urihttps://hdl.handle.net/11443/1309
dc.identifier.urihttp://dx.doi.org/10.3109/0886022X.2011.647338
dc.identifier.wosWOS:000300558700022
dc.publisherTAYLOR \& FRANCIS LTD
dc.relation.ispartofRENAL FAILURE
dc.subjectencapsulating peritoneal sclerosis
dc.subjecttamoxifen
dc.subjecteverolimus
dc.titleAdditive Effectiveness of Everolimus Plus Tamoxifen Therapy in Treatment of Encapsulating Peritoneal Sclerosis
dc.typeArticle

Files

Collections

WOS